GlassScriptPhysician profile
Nicole E Pisapia
NPI 1952743411
$2,048.90
in general payments reported to CMS, 2019-2025
21 companies · $94.63 in 2025
The $94.63 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $870 · 2021: $23.18 · 2022: $53.83 · 2023: $161 · 2024: $140 · 2025: $94.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.27 | 2019-2020 | |
| Pfizer INC. | $221.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.15 | 2019-2023 | Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $203.91 | 2019-2020 | |
| Janssen Biotech, INC. | $143.53 | 2019-2020 | |
| Boston Scientific Corporation | $133.97 | 2019-2024 | Compliance Endokit |
| Gilead Sciences, INC. | $132.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $108.22 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $96.88 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $62.19 | 2019-2020 | |
| Braintree Laboratories, INC. | $39.83 | 2020 | |
| Portola Pharmaceuticals, LLC | $36.84 | 2019-2020 | |
| Daiichi Sankyo INC. | $33.64 | 2020 | |
| Merck Sharp & Dohme LLC | $31.23 | 2019 | |
| Madrigal Pharmaceuticals | $28.69 | 2024 | Resmetirom |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.35 | 2025 | Wegovy |
| Micro-Tech Endoscopy USA, INC. | $16.95 | 2025 | Eyemax |
| Echosens North America, INC. | $15.46 | 2025 | Fibroscan |
| Alfasigma USA, INC. | $14.47 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.95 | 2019 | |
| Shionogi INC | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Pisapia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.